Medine.co.uk

Metoclopramide 5mg/Ml Solution For Infusion

Document: leaflet MAH GENERIC_PL 20072-0052 change

Front side


Back side


Zona reservada para cfidigo visual


Package Leaflet: Information for the patient XXXXXX/LF/069/02    8093548-04

Metoclopramide 5mg/ml Solution for Infusion

(metoclopramide hydrochloride BP)


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

-    Keep this leaflet. You may need to read it again.

-    If you have any further questions, ask your doctor or pharmacist or nurse.

-    If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

The name of your medicine is Metoclopramide 5mg/ml Solution for Infusion but it will be referred to as Metoclopramide Infusion in the rest of the leaflet.

What is in this leaflet

1.    What Metoclopramide Infusion is and what it is used for

2.    What you need to know before you take Metoclopramide Infusion

3.    How to take Metoclopramide Infusion

4.    Possible side effects

5.    How to store Metoclopramide Infusion

6.    Contents of the pack and other information

1. What Metoclopramide Infusion is and what it is used for

This product is an antiemetic. It contains a medicine called “metoclopramide”. It works on a part of your brain that prevents you from feeling sick (nausea) or being sick (vomiting).

Adult population

Metoclopramide is used in adults:

-    to prevent nausea and vomiting that may occur after surgery

-    to treat nausea and vomiting including nausea and vomiting which may occur with a migraine

-    to prevent nausea and vomiting caused by radiotherapy. Paediatric population

Metoclopramide is used in children (aged 1 -18 years)

£1 only if other treatment does not work or cannot be used:

-    to prevent delayed nausea and vomiting that may occur after chemotherapy

-    to treat nausea and vomiting that has occurred after surgery.

___2. What you need to know before you take_____

Metoclopramide Infusion Do not take Metoclopramide Infusion:

•    If you are allergic to metoclopramide or any of the other ingredients of this medicine (listed in section 6)

•    If you have bleeding, obstruction or a tear in your stomach or gut

•    If you have or may have a rare tumour of the adrenal gland, which sits near the kidney (pheochromocytoma)

•    If you have ever had involuntary muscle spasms (tardive dyskinesia), when you have been treated

kg    with a    medicine

If    •    If you    have epilepsy

•    If you    have Parkinson’s disease

•    If you    are taking levodopa    (a    medicine for

Parkinson’s disease) or dopaminergic agonists (see below “Other medicines and Metoclopramide”)

•    If you have ever had an abnormal blood pigment levels (methaemoglobinemia) or NADH cytochrome-b5 deficiency.

Do not give Metoclopramide to a child less than 1 year of age (see below “Children and adolescents”). Do not take Metoclopramide if any of the above applies to you.

If you are not sure, talk to your doctor, pharmacist or nurse before you take Metoclopramide.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Metoclopramide:

•    If you have a history of abnormal heart beats (QT interval prolongation) or any other heart problems

•    If you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium

•    If you are using other medicines known to affect the way your heart beats

•    If you have any neurological (brain) problems

•    If you have liver or kidney problems. The dose may be reduced (see section 3).

Your doctor may perform blood tests to check your blood pigment levels. In cases of abnormal levels (methaemoglobinemia), the treatment should be immediately and permanently stopped.

Children and adolescents

Uncontrollable movements (extrapyramidal disorders) may occur in children and young adults. This medicine must not be used in children below 1 year of age because of the increased risk of the uncontrollable movements (see above “Do not take Metoclopramide if”).

Other medicines and Metoclopramide Infusion

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because some medicines can affect the way


O

AMDIPHARM


Metoclopramide works or Metoclopramide can affect how other medicines work. These medicines include the following:

-    levodopa or other medicines such as bromocriptine and pergolide used to treat Parkinson’s disease (see above “Do not take Metoclopramide if”)

-    anticholinergics such as phenothiazines and tetrabenazine (medicines used to relieve stomach cramps or spasms)

-    morphine derivatives (medicines used to treat severe pain)

-    sedative medicines

-    any medicines used to treat mental health problems

-    digoxin (medicine used to treat heart failure)

-    cyclosporine (medicine used to treat certain problems with the immune system)

-    mivacurium and suxamethonium (medicines used to relax muscles)

-    fluoxetine and paroxetine (medicine used to treat depression)

-    medicines used to treat pain such as paracetamol and aspirin

-    medicines used to treat infections such as antiprotozoals (atovaquone).

Metoclopramide Infusion with food, drink and alcohol

Alcohol should not be consumed during treatment with metoclopramide because it increases the sedative effect of Metoclopramide.

Pregnancy, breast-feeding and fertility Pregnancy:

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before being given this medicine. If necessary, Metoclopramide may be taken during pregnancy. Your doctor will decide whether or not you should be given this medicine.

Breast-feeding

Metoclopramide is not recommended if you are breast-feeding because metoclopramide passes into breast milk and may affect your baby.

Driving and using machines

You may feel drowsy, dizzy or have uncontrollable twitch irfg .“fe rKm g-orwrithingmovements ancTunusual-muscle tone causing distortion of the body after taking Metoclopramide. This may affect your vision and also interfere with your ability to drive and use machines.

Metoclopramide Infusion contains sodium

This medicinal product contains less than 1 mmol sodium (23mg) per 6 ml, i.e. essentially ‘sodium- free’.

3. How to take Metoclopramide Infusion

The medicine will normally be given to you by a doctor or a nurse. It will be given as a slow injection into a vein (over at least 3 minutes) or by injection into a muscle.

Dose:

In adults population

The usual dose given to adults is 2-4 mg/kg of body weight for the first 15-20 minutes before you receive your radiotherapy or other antitumour medicine. The dose will then change to 3-5 mg/Kg of body weight either over the course of a few hours or repeated every 2 hours for 15 minutes.

For the treatment of nausea and vomiting including nausea and vomiting which may occur with a migraine and for the prevention of nausea and vomiting caused by radiotherapy: the recommended single dose is 10 mg, repeated up to 3 times daily.

The maximum recommended dose per day is 30 mg or 0.5 mg/kg body weight.

For the prevention of nausea and vomiting that may occur after surgery prevention: a single dose of 10mg is recommended.

Use in children and adolescents

The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to 3 times daily, given by slow injection into a vein.

The maximum dose in 24 hours is 0.5 mg/kg body weight.


Dosing table

Age

Body

Weight

Dose

Frequency

1-3 years

10-14 kg

1 mg

Up to 3 times daily

3-5 years

15-19 kg

2 mg

Up to 3 times daily

5-9 years

20-29 kg

2.5 mg

Up to 3 times daily

9-18 years

30-60 kg

5 mg

Up to 3 times daily

15-18 years

Over 60 kg

10 mg

Up to 3 times daily


a a


n 3.


Sentido de lectura del laetus    .    Sentido de lectura del laetus


A


5 mm


10 mm


40 mm


15 mm


I a


cn

(0

o

Q.

CD

US


Device / instruction for use

You should not take this medicine for more than 5 days to prevent delayed nausea and vomiting that may occur after chemotherapy.

Metoclopramide Infusion will be given to you as a drip, usually over a few hours. Your doctor will work out the correct dose for you based on your weight.

Elderly

The dose may need to be reduced depending on kidney problems, liver problems and overall health.

Adults with kidney problems

Talk to your doctor if you have kidney problems. The dose should be reduced if you have moderate or severe kidney problems.

Adults with liver problems

Talk to your doctor if you have liver problems. The dose should be reduced if you have severe liver problems.

Children and adolescents

Metoclopramide must not be used in children aged less than 1 year (see section 2).

If you take more Metoclopramide Infusion than you should

Contact your doctor or pharmacist straight away. You may experience uncontrollable movements (extrapyramidal disorders), feel drowsy, have some troubles of consciousness, be confused, have hallucination and heart problems. Your doctor may prescribe you a treatment for these signs if necessary.

If you forget to take Metoclopramide Infusion

Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.

4. Possible side effects

Like all medicines, Metoclopramide Infusion can cause side effects although not everybody gets them.

Stop the treatment and talk straight away to your doctor, pharmacist or nurse if you experience one of the following signs while having this medicine:

•    uncontrollable movements (often involving head or neck). These may occur in children or young adults and particularly when high doses are used. These signs usually occur at the beginning of treatment and may even occur after one single administration. These movements will stop when treated appropriately. (Frequency of these side effects is common- may affect up to 1 in 10 people)

"• “highfever/hTgh^Ibbd^ressufeTcdnvuTsibhsr “ sweating, production of saliva. These may be signs of a condition called neuroleptic malignant syndrome. (Frequency of this side effect is not known- (frequency cannot be estimated from the available data)

•    itching or skin rashes, swelling of the face, lips or throat, difficulty in breathing. These may be signs of an allergic reaction, which may be severe. (Frequency of this side effect is not known-frequency cannot be estimated from the available data)

•    convulsions (especially in patients with epilepsy). (Frequency is rare- may affect up to 1 in 1,000 people)

•    allergic reaction which may be severe (particularly with intravenous route). (Frequency of this side effect is not known- (frequency cannot be estimated from the available data)

•    shock (severe decrease of heart pressure) (particular with injection route).(Frequency of this side effect is not known- (frequency cannot be estimated from the available data)

•    very high blood pressure. (Frequency of this side effect is not known- (frequency cannot be estimated from the available data).

Very common (may affect more than 1 in 10 people)

•    feeling drowsy.

Common (may affect up to 1 in 10 people)

•    depression

•    symptoms similar to Parkinson disease (rigidity, tremor)

•    feel restless

•    blood pressure decrease (particularly with intravenous route)

•    diarrhoea

•    feeling weak.

Uncommon (may affect up to 1 in 100 people)

•    raised levels of a hormone called prolactin in the blood which may cause: milk production in men, and women who are not breast-feeding

•    irregular periods

•    hallucination

•    decreased level of consciousness

•    slow heartbeat (particularly with intravenous route) allergy.

Rare (may affect up to 1 in 1,000 people)

•    confusional state.


Not known (frequency cannot be estimated from the available data)

•    abnormal blood pigment levels: which may change the colour of your skin

•    abnormal development of breasts (gynaecomastia)

•    involuntary muscle spasms after prolonged use, particularly in elderly patients

•    changes in heart beat, which may be shown on an ECG test

•    cardiac arrest (particularly with injection route)

•    fainting (particularly with intravenous route)

•    dyspnoea (difficulty breathing)

•    Sudden increase in blood pressure in patients with tumour of the adrenal gland (pheochromocytoma)

•    very high blood pressure.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report any side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

5.    How to store Metoclopramide Infusion

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is printed on the carton after EXR The expiry date refers to the last day of that month.

Protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6.    Contents of the pack and other information What Metoclopramide Infusion contains

Metoclopramide Infusion contains 100 mg of the active ingredient metoclopramide hydrochloride. The other inactive ingredients are: sodium chloride and water for injections.

What Metoclopramide Infusion looks like and contents of the pack

Metoclopramide Infusion is a clear, colourless solution available in clear glass 20 ml ampoules, packed in boxes of 10.

Marketing Authorisation Holder and Manufacturer

Amdipharm UK limited,

Capital House,

85 King William Street,

EbhdbfrEC4N7BL,“DK_

Manufacturer responsible for release:

Kern Pharma SL,

Poligono Ind. Colon II,

C/Venus 72,08228 Terrassa,

Barcelona, Spain.

This leaflet was last revised in August 2016.


/ \

0

AMDIPHARM

Version No.:

XXXXXX/LF/069/02

Product Name:

Metoclopramide

5mg/ml Solution for

Infusion

Pack Size:

10 Ampoules

Component:

Leaflet

SKU:

xxxxxx

Market:

UK

Production Site:

Kern Pharma

Revision No.:

2

Revision Date:

25/08/2016

Revised by:

PAT

CRF:

PR 5454

V

y

Dimension:

173 x 455 mm

Commodity No.:

8093548-04

Pharma Code:

N/A

Core Spec Ref:

N/A

DCMF:

N/A

Print Colours:

Black

Non-Print Colours:

Cutler

Tech App. Date:

No

Min. Font Size:

10 pt

V

y

f-\

REGULATORY AUTHORITY APPROVAL CONFIRMATION


Confirmation that this artwork has been approved by the appropriate market authority (if applicable, e.g. MHRA, HPRA, etc.) and that Amdipharm have license approval to distribute this component for sale in the relevant market.


Accept Artwork / Reject Artwork

(Please strike off whichever NOT applicable)


Signature

Name

PAGE 1 OF 1

V_/


455 mm


173 mm